CRF Health Announces an Open ePRO Integration Interface
CRF Health
announced an open ePRO integration interface, which enables Sponsors and CROs to integrate their own eClinical systems with CRF Health’s ePRO platform, TrialMax, to provide data collected from patients in real time to all study stakeholders.
The TrialMax Synapse open interface integrates ePRO data collected with CRF Health’s TrialMax platform to other eClinical systems in real time using the CDISC ODM standard. The current studies integrated to a EDC system are seeing a variety of benefits, including the enabling of sites to view all study data in one system, increasing the efficiency of drug accountability, facilitating data management, and allowing easier correlation of adverse events.
Rachael King, CEO of CRF Health, comments, “We have seen a significant increase in interest for integrating ePRO data to other eClinical systems, and are currently using integration in several studies. As the use of integration has exceeded all of our expectations, we decided to offer the possibility to all Sponsors and CROs that we are working with.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
